Y-Intercept (HK)’s Karyopharm Therapeutics KPTI Stock Holding History

Y-Intercept (HK)’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$101K	Buy	+10,375	New	+$90K	﹤0.01%	1613
2024 Q3	–	Sell	-27,397	Closed	-$357K	–	1571
2024 Q2	$357K	Buy	+27,397	New	+$454K	0.02%	966
2023 Q3	–	Sell	-2,262	Closed	-$60.7K	–	1344
2023 Q2	$60.7K	Buy	+2,262	New	+$97.4K	0.01%	1186
2023 Q1	–	Sell	-1,006	Closed	-$51.3K	–	1361
2022 Q4	$51.3K	Buy	1,006 +315	+46%	+$21.8K	0.01%	917
2022 Q3	$56.6K	Buy	+691	New	+$51.6K	0.01%	906

Other funds holding KPTI

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

WBC

West Branch Capital Amherst, Massachusetts $430M AUM 41.9% 1-Year Est. Return

Y-Intercept (HK)'s KPTI Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in Karyopharm Therapeutics (KPTI) in Q2 2026: 10,375 shares worth $101K. The stake represents ﹤0.01% of the portfolio and ranks #1613 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in KPTI as recently as Q2 2024.

Y-Intercept (HK) first reported a position in KPTI in Q3 2022 and has held it in 5 quarters since. The position peaked at $357K in Q2 2024. 3 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

Y-Intercept (HK) held 10,375 shares of Karyopharm Therapeutics worth $101K as of Q2 2026.
Karyopharm Therapeutics was a new Y-Intercept (HK) position in Q2 2026.
Karyopharm Therapeutics made up ﹤0.01% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1613 holding.
Y-Intercept (HK) first reported a position in Karyopharm Therapeutics in Q3 2022 and has held it in 5 quarters since.
Y-Intercept (HK)'s Karyopharm Therapeutics position peaked at $357K in Q2 2024.
3 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.